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Fig. 1 Histological examples of the growth patterns that had been
adopted to variable extent after the ISUP 2005 consensus meeting
but unanimously incorporated into distinct Gleason grades and Grade
Groups at the 2014 ISUP consensus meeting. A, Separate glands
should be assigned a Gleason grade pattern 3, regardless of the size
or, for example mucinous excretion (arrowheads). Fusing glands of
Gleason grade pattern 4 shown on the right, partially perineurally (ar-
rows). B, Cribriform and glomeruloid glands are assigned as Gleason
grade pattern 4 (open arrows), regardless of the size (Gleason grade
pattern 3 glands shown in comparison, arrowheads). Intraductal carci-
noma (asterisk) should not be given a Gleason grade.
Table 1 Gleason Score versus Grade Group
Gleason Score Grade Group
≤6 1
3 + 4 2
4 + 3 3
4 + 4
5 + 3 4
3 + 5
4 + 5
5 + 4 5
5 + 5
160 A. Erickson et al.1. Introduction
Gleason grading holds the position as the strongest predic-
tor of survival after initial treatment of prostate cancer. Since
the introduction of the Gleason grade patterns and score in
1966, the modifications done to the overall Gleason score
(GS) over the years have led to clustering of new prostate can-
cer diagnoses mainly into GS 6 and 7 [1-3]. The current con-
sensus is that no GS 2-4 should be assigned in biopsies and
even GS 5 is very rare [4]. There is strong evidence that GS
3 + 4 = 7 and 4 + 3 = 7 differ in terms of survival [5,6]. As
a whole, the aforementioned “grade inflation" and sources of
confusion for the patients have led to a consensus work-up
for a new Grade Group (GG) system recently introduced in
the World Health Organization classification for prostate can-
cer [4,7-9]. Histologically, the variable adaptation of the mod-
ifications to Gleason grading after the International Society of
Urological Pathology (ISUP) 2005 consensus meeting have
now been incorporated into a consensus statement withuniform acceptance, and grading is performed with more uni-
fied criteria (Fig. 1). The new grading system allows for easier
counseling of patients and has potentially increased predictive
value over GS. GGs are formed from the contemporary GS cri-
teria (Table 1). Tertiary patterns, now suggested to be referred
to as minor high-grade patterns (MHGP), have also been con-
sidered in the context of GGs as recent studies have shown that
MHGP can potentially add prognostic value to GG. MHGP,
however, are not currently considered as an integral part of
the GG and are only assessed in radical prostatectomy (RP)
specimens [10]. The validation studies for GG thus far have
shown the relation of GG to biochemical recurrence-free sur-
vival (BRFS) and prostate cancer–specific mortality (PCSM) in
RP cohorts, using biopsy and/or RP grades [11-13]. Registry-
based re-analyses have shown the strength of GG in predicting
PCSM and metastasis-free survival [14]. Also recently, a radi-
ation-treated cohort was analyzed for biopsy GG as predictor
of BRFS and PCSM [15]. However, none of the studies have
shown that the new GG system has increased predictive power
with respect to GS, and most of the studies are hampered by
short follow-up times and BRFS as the end-point for the
analysis.
The weakness for BRFS as end-point is its surrogate nature
[16-18]. Altogether, 30%–40% of RP-treated patients experi-
ence BRFS during post-operative follow-up [19-21]. How-
ever, presumably by the survival-prolonging effect of
secondary treatments, only approximately 10% of the patients
experience disease-specific mortality in 10 to 15 years after RP
[22,23]. Cohorts with an adequate number of patients and suf-
ficient follow-up time for PCSM are rarely available. In addi-
tion, pre–magnetic resonance imaging (MRI)–era transrectal
ultrasound–guided (TRUS) biopsies are prone to significant
sampling error, thus higher grade prostate cancer foci are
missed in up to 30% of GS 3 + 3 biopsies [24,25]. Validation
of the GG system in predicting the all-cause mortality (ACM)
and PCSM compared to conventional Gleason grade pattern
scores is essential in order to facilitate its use in patient com-
munication. Here, we have validated the predictive signifi-
cance of the new GG system after RP in a large patient set
with substantially long follow-up time. In addition to the most
important outcome, ie, survival, secondary treatment informa-
tion was incorporated into the analysis.






Age at RP, years (n = 831) (median, range) 64 (45-76) 62 (40-73) 63 (40-76)
Diagnostic PSA, ng/mL (n = 715) (n, %)
≤10.0 145 (50.0) 294 (69.2) 439 (61.4)
10.1-20.0 92 (31.7) 96 (22.6) 188 (26.3)
N20.0 53 (18.3) 35 (8.2) 88 (12.3)
Gleason score at RP (n = 831) (n, %)
≤6 97 (25.9) 168 (36.8) 265 (31.9)
7 217 (58.0) 197 (43.1) 414 (49.8)
8-10 60 (16.0) 92 (20.1) 152 (18.3)
Grade Group at RP (n = 831) (n, %)
1 97 (25.9) 168 (36.8) 265 (31.9)
2 95 (25.4) 134 (29.3) 229 (27.6)
3 122 (32.6) 63 (13.8) 185 (22.3)
4 47 (12.6) 70 (15.3) 117 (14.1)
5 13 (3.5) 22 (4.8) 35 (4.2)
pT (n = 784) (n, %)
2 208 (60.5) 233 (53.0) 441 (56.2)
3 136 (39.5) 207 (47.0) 343 (43.8)
Lymph node status (n = 822) (n, %)
N0 358 (97.3) 434 (95.6) 792 (96.4)
N1 10 (2.7) 20 (4.4) 30 (3.6)
Follow-up time after RP, years (n = 831) (median, range) 15.7 (0.1-28.6) 9.5 (0.2-14.0) 11.1 (0.1-28.6)
Death from any cause (n = 831) (n, %) 183 (48.9) 73 (16.0) 256 (30.8)
Death from prostate cancer (n = 831) (n, %) 36 (9.6) 19 (4.2) 55 (6.6)
Patients receiving secondary therapy (n = 812) (n, %) 128 (34.2) 136 (31.1) 264 (31.8)
Abbreviations: RP, radical prostatectomy; PSA, prostate-specific antigen; pT, pathological stage.
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2.1. Patient cohort
The study cohort consisted of patients with comprehensive
clinical data and accompanying RP specimens operated on
between 1983 and 1998 at Helsinki University Hospital and
between 2000 and 2005 at Turku University Hospital. Limited
pelvic lymph node dissection accompanied most of the RPs in
both cohorts. The clinical databases were combined and
updated in November 2015with the Finnish Cancer Registry's
data on patients' all-cause and disease-specific mortality,
resulting in a median follow-up time of 15.7 years for the
Helsinki cohort (range 0.7-28.6) and 9.5 years (range 0.2-
14.0) for the Turku cohort. The median post-RP follow-up
time for the entire cohort for PCSM and ACMwas 11.9 years,
and the median age at RP was 62.4 years. For more detailed
demographics of the separate Helsinki and Turku cohorts
and the whole cohort, see Table 2.
The Helsinki and Turku cohorts originally included 478
and 532 patients, respectively. For both cohorts, the original
clinical RP specimen slides were re-evaluated between years
2005 and 2010 by experienced uropathologists according to
the GS criteria of the ISUP 2005 consensus meeting and taking
into account the commonly applied recommendationsthereafter, to form the classes currently recognized as GGs
(the criteria that were approved in the consensus of 2014)
(Table 1) [1,2,26]. To avoid possible interference of accompa-
nied treatments on tissue interpretation [1], patients who had
received neoadjuvant therapies prior to RP were excluded,
leading to 401 and 503 patients in the Helsinki and Turku
cohorts, respectively. Complete follow-up data were available
for a total of 374 and 457 patients, who were included in the
final analysis. Post-operative follow-up was conducted by
clinical examinations and prostate-specific antigen (PSA)
measurements at least three times during the first year after
surgery and at least once a year during the following years.
For the Helsinki cohort, also the complete information of the
commencement dates for secondary therapies was available
(Supplementary Table 1).
The ethical committees of the corresponding hospital dis-
tricts approved the use of clinicopathological data (Hospital
District of Helsinki and Uusimaa, 445/E6/02, and Hospital
District of Southwest Finland). Approval for the use of clinical
and registry data was obtained from the National Authority for
Welfare and Health (Valvira 394/05.01.00.06/2009) and the
use of the Finnish Cancer Registry's data was approved by
the National Institute for Health and Welfare (THL/1549/
5.05.00/2013). Patients' personal information was de-
identified prior to analyses.
162 A. Erickson et al.2.2. Statistical analysis
The primary outcomes in this study were PCSM and ACM
within the first 15 years of follow-up. If outcome events oc-
curred after 15 years, the patient's follow-up was encoded as
15 years, and censored. The secondary outcome, analyzed
only in the Helsinki cohort, was initiation of secondary ther-
apy. Kaplan-Meier survival analysis with Mantel-Haenzel
log-rank test for time to PCSM, time to ACM or time to sec-
ondary therapies was performed. Additionally, univariable
and multivariable Cox regression analyses were performed to
assess risk for outcome events, and included age at operation,
PSA at diagnosis, GG, pathological T-stage (pT), and lymph
node status in the models. Competing risk analysis was per-
formed comparing the risk of mortality by any causes and by
prostate cancer, as stratified by GG. Receiver operating char-
acteristic (ROC) area under the curve (AUC) analyses were
performed for the new 5-tiered GG and 3-tiered GS (b7, 7,
N7) to compare the predictive accuracy of the two grading sys-
tems. Decision curve analyses comparing net benefit of Grade
Grouping versus Gleason scoring in the decisionmaking was
also performed. All statistical analyses were performed using
R Statistical Software v.3.3.3 (Foundation for Statistical Com-
puting, Vienna, Austria) using the packages survival, survmi-
ner, pROC, cmprsk, and rms.3. Results
3.1. Univariable survival analysis
Amongst the study population, half of the patients were
originally graded as GS7 and almost one third as GS ≤ 6. Af-
ter stratifying patients into GGs, GG2 and GG3 formed almost
equally sized groups (Table 2). In Kaplan-Meier survival anal-
yses for ACMand PCSMoutcomes, remarkably, GG2 stratified
patients similarly to GG1, while the survival profile of patients
with GG3 was similar to those patients with GG4 or GG5 (P
.0001, Fig. 2A and B). Each unit increase in GG was signifi-
cantly associated with shorter median secondary therapy
treatment-free survival (P b .0001, Supplementary Fig. 1).
In univariable Cox proportional hazard analysis for proba-
bility of death after surgical treatment, the hazard ratio for
PCSM ranged from 8.015 (P = .052, 95% CI = 0.986-
65.14) to 55.799 (P b .001, 95% CI 6.717-463.52) whenig. 2 Survival analysis of new Grade Group system and out-
omes. Kaplan-Meier analyses for probability of survival during fol-
w-up for prostate cancer–specific mortality (PCSM)–free survival
), any cause mortality (ACM)–free survival (B). To evaluate the
ew Grade Grouping system with regards to significance in predict-
g competing outcomes, Gray's competing risk analysis (C) was per-
rmed for low (1-2) versus high (3-5) and cumulative incidence of
ny-cause mortality within 15 years of follow-up (ACM15) and pros-










Table 3 Uni- and multivariate Cox regression analysis of clinicopathological variables and outcome
Variable Univariate Multivariate
HR 95% CI P HR 95% CI P
A. Prostate cancer–specific mortality within 15 years of follow-up
Age at RP ≤60 y – – Ref – – Ref
Age at RP 60.1–70 y 1.137 (0.599-2.156) .695 1.908 (0.799-4.553) .146
Age at RP N70 y 1.660 (0.603-4.568) .327 0.616 (0.075-5.054) .652
PSA at diagnosis 0-10.0 – – Ref – – Ref
PSA at diagnosis 10.1-20.0 1.902 (0.806-4.486) .142 1.514 (0.623-3.678) .360
PSA at diagnosis N20 2.913 (1.127-7.528) .027 ⁎ 1.145 (0.411-3.188) .795
Grade Group 1 a – – Ref – – Ref
Grade Group 2 8.015 (0.986-65.14) .052 2.699 (0.861-8.464) .089
Grade Group 3 27.315 (3.656-204.06) .001 ⁎ 6.692 (2.215-20.218) .001⁎
Grade Group 4 37.136 (4.905-281.16) b.001 ⁎ 7.797 (2.037-29.843) .003⁎
Grade Group 5 55.799 (6.717-463.52) b.001 ⁎ – – Ref
pT stage 2 – – Ref 6.224 (1.823-21.247) .004⁎
pT stage 3 and 4 16.544 (5.088-53.8) b.001 ⁎ – – Ref
LN negative – – Ref 17.481 (4.883-62.582) b.001 ⁎
LN positive in first 6 years 16.068 (6.018–42.90) b.001 ⁎ 1.917 (0.24-15.289) .539
LN positive after first 6 years 4.624 (1.399-15.28) .012 ⁎
B. Any-cause mortality within 15 years of follow-up
Age at RP ≤60 y – – Ref – – Ref
Age at RP 60.1–70 y 1.217 (0.882-1.681) .232 1.281 (0.887-1.85) .186
Age at RP N70 y 2.933 (1.918-4.486) b.001 ⁎ 2.807 (1.664-4.737) b.001 ⁎
PSA at diagnosis 0-10.0 – – Ref – – Ref
PSA at diagnosis 10.1-20.0 0.967 (0.667-1.402) .858 0.879 (0.599-1.29) .510
PSA at diagnosis N20 1.515 (0.997-2.302) .052 0.886 (0.553-1.421) .616
Grade Group 1 – – Ref – – Ref
Grade Group 2 1.181 (0.772-1.807) .444 0.928 (0.569-1.513) .763
Grade Group 3 2.025 (1.368-2.997) b.001 ⁎ 1.291 (0.784-2.126) .315
Grade Group 4 2.749 (1.805-4.188) b.001 ⁎ 1.784 (1.044-3.047) .034⁎
Grade Group 5 2.861 (1.536-5.331) b.001 ⁎ 1.823 (0.864-3.845) .115
pT stage 2 – – Ref – – Ref
pT stage 3 and 4 1.940 (1.447-2.601) b.001 ⁎ 1.520 (1.056-2.188) .024⁎
LN negative – – Ref – – Ref
LN positive 3.649 (2.247-5.925) b.001 ⁎ 3.492 (1.899-6.419) b.001 ⁎
C. Initiation of secondary therapy
Age at RP ≤60 y – – Ref – – Ref
Age at RP 60.1–70 y 0.832 (0.481-1.439) .510 1.226 (0.786-1.911) .369
Age at RP N70 y 0.876 (0.376-2.043) .760 1.556 (0.830-2.917) .168
PSA at diagnosis 0-10.0 – – Ref – – Ref
PSA at diagnosis 10.1–20.0 2.152 (1.162-3.983) .015 ⁎ 1.896 (1.041-3.454) .037⁎
PSA at diagnosis N20 4.047 (2.235-7.327) b.001 ⁎ 6.942 (3.957-12.177) b.001 ⁎
Grade Group 1 – – Ref – – Ref
Grade Group 2 1.676 (0.626-4.487) .304 3.376 (1.442-7.903) .005
Grade Group 3 2.920 (1.139-7.487) .026 ⁎ 7.566 (3.421-16.735) b.001 ⁎
Grade Group 4 6.799 (2.455-18.828) b.001 ⁎ 12.546 (5.396-29.172) b.001 ⁎
Grade Group 5 26.208 (7.785-88.23) b.001 ⁎ 25.591 (9.478-69.097) b.001 ⁎
pT stage 2 – – Ref – – Ref
pT stage 3 and 4 2.959 (1.747-5.012) b.001 ⁎ 4.586 (3.039-6.919) b.001 ⁎
LN negative – – Ref – – Ref
LN positive 1.406 (0.404-4.895) .593 4.87 (2.128-11.14) b.001 ⁎
Abbreviations: RP, radical prostatectomy; PSA, prostate-specific antigen; pT, pathological stage; LN, lymph node.
a Grade Groups 1 and 2 pooled for multivariate analysis.
⁎ Statistically significant P-value, 2-tailed.
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164 A. Erickson et al.GG2 to GG5 were compared to reference of GG1. Similarly,
increased GG was associated with increased risk of ACM
and initiation of secondary therapy (Table 3).
3.2. Multivariable survival analysis
In testing Cox proportional hazards assumption for a multi-
variable model with PCSM as the outcome, the lymph node sta-
tus at RP was found to violate the assumption, and was assessed
in a time-dependent manner of less than or equal to 6 years
follow-up, or greater than 6 years follow-up. Additionally, due
to the low number of PCSM events in GG1 (n = 1), our multi-
variable model did not converge, and thus we conducted
pooled analysis of GG1 and 2 together as the reference group.
In the multivariable Cox regression analysis, pT stage and
lymph node positivity predicted significant differences in
PCSM. Interestingly, the increased risk of outcome events
due to lymph node positivity was observed to be time
dependent, with it no longer being associated with PCSM after
the first 6 years of follow-up (Table 3A).
3.3. Competing risk analysis of cause of mortality
Gray's competing risk analysis was conducted to analyze
the predicted risk of patients with GG 1 and 2, versus GG 3-
5 PC progressing to PCSM in comparison to patients who ex-
perienced ACM or survival. There was a significant difference
of cumulative incidence by GG in patients who experienced
PCSM (P b .0001) and ACM (P = .046) (Fig. 2C).
3.4. Benefits of Grade Grouping in outcome prediction
In order to study the additive effect of GG in survival pre-
diction, ROC-AUC analyses were performed to address the
discriminatory power of three-tier GS (b7, 7, N7) and the
five-tier GG with outcomes. The receiver-operating curve dis-
criminatory analysis showed increased area under the curve
(AUC) values for GG in all of the study outcomes when com-
pared with the three-tier GS (Supplementary Fig. 2A-C).
Lastly, decision curve analyses were performed to
compare the net benefit of GG and GS in predicting outcome.
Decision curve analysis plots the net benefit of predictors
against all probabilities of an event occurring. This allows
for comparison of different predictors in assessing the harm-
to-benefit ratio for clinical decision of an intervention.
For all measured outcomes (PCSM, ACM and secondary
therapy–free survival), across all threshold probabilities of
outcome events occurring, GG performed better than, or as
well as, GS (Supplementary Fig. 3).4. Discussion
A new predictive prostate cancer grading system has re-
cently been proposed by authors at Johns Hopkins Hospitalled by the pathologist Jonathan Epstein using a fairly simple
division of Gleason grade pattern sums into GG (Table 1)
[4]. The predictive value has been validated in studies of pros-
tate cancer patients treated with different modalities as well as
in separate cohorts of RP and radiation-treated patients
[12,14,27]. Despite studies assessing the predictive value of
GG to predict hard outcomes such as PCSM [13], few studies
have comprehensively conducted rigorous discriminatory
analysis of GS and GG in the same patient cohort.
Previous studies have compared GG and GS in prediction
of BRFS [15,27,28] and have found GG to be a better predic-
tor of outcome than GS. The strengths of these studies include
large sample sizes, multi-center analyses, and diverse study
populations. The studies, however, suffer from short median
follow-up times, and the use of BRFS, which is considered
as a surrogate endpoint. Additionally, as commented by
Dell'Oglio et al, these studies did not address the most crucial
unmet clinical need: assessing the possible superiority of GG
over GS with regard to harder outcomes, namely PCSM
[29]. In order to address these problems, two other recently
published studies, have analyzed harder endpoints [30,31]. In
the study by Dell'Oglio et al, no additive benefit for GG over
GS could be shown. The authors assessed performance with
respect to clinical recurrence (CR), defined as detection of me-
tastasis after BRFS, as an endpoint and a median follow-up of
5.8 years [30]. The authors speculated that a lack of plateau in
their Kaplan-Meier curves might suggest increased differences
between GGs with longer follow-up. The study by Grogan
et al compared the predictive power of GG and GS for BRFS,
CR, and PCSM in a single-center cohort. The study cohort fea-
tured a rigorous re-evaluation of GS to the ISUP 2005 standard,
and a long median follow-up time of 15 years. While their study
found GG to be superior to GS in predicting BRFS, CR and
PCSM, the authors did not report whether GG remained an inde-
pendent predictor of PCSM in multivariable analysis for PCSM,
despite reporting such data for other study outcomes [31].
To our knowledge, our study is the first multicenter study,
with long-term follow-up, to demonstrate increased predictive
value of GG over GS in predicting PCSM and ACM. Our
study, with a median of 11.1 years follow-up, affirms the
power of GG to predict long-term survival in a RP-treated co-
hort. Our patients had not received neoadjuvant treatments, but
had been treated with adjuvant or secondary therapies at any
given era according to treating urologist's discretion. Given
the fact that GG remarkably associated with probability of re-
ceiving secondary therapies and stratified each group to sepa-
rate survival curves, only patients in GGs 3 to 5 progressed to
prostate cancer–specific death in significant numbers. It is also
obvious that the greater adjuvant therapy with each successive
GG likely lessened the separation of the curves in the cancer-
specific mortality Kaplan-Meier curves (Fig. 2A) since adju-
vant therapy is associated with delaying the time to death.
One of the strengths of our study compared to other con-
temporary cohorts is the long median follow-up time needed
to study survival endpoints [14]. Only by long follow-up can
the significant variables independently associated with
165Grade grouping in prostate cancer survival predictionPCSM be assessed, those being age, diagnostic, pT stage,
lymph node status and GG in our multivariable analysis. Re-
gardless of the local extent of the disease, GG predicted
PCSM after RP. Especially the clear depression in survival
probability seen between GG2 and GG3 emphasizes the im-
portance of volume of Gleason grade pattern 4 predominance
long term for contributing to disease progression and mortal-
ity, despite secondary therapies. All of our patients have been
diagnosed before 2005, and thus the treatment decisions were
based on the Gleason criteria at that time. Importantly, as we
aimed for long follow-up to allow survival endpoints to be
studied, we chose a historical cohort, but re-evaluation of the
slides was conducted according to 2005 ISUP consensusmeet-
ing, supplemented by the modifications later approved in
2014. Our study with re-evaluated RP specimens further states
the use of GG in differentiation of Gleason score 7 tumors into
groups with significantly different prognosis.
In addition to being a retrospective analysis, other weak-
nesses of our study include lack of thorough PSA data for
BRFS analysis and the lack of information on the tertiary
Gleason pattern in RP specimens. A recent study has evaluated
how the existence of tertiary higher-grade pattern along with
the newGG affects the prognosis after RP [32]. Also, as the bi-
opsies are now more often taken under MRI-TRUS fusion
guidance, the issues of undersampling can be better avoided
[24]. Based on our results on RP-treated cohorts, we can pos-
tulate that GG2 patients react to adjuvant treatments better and
can possibly be treated more conservatively post-operatively,
or followed-up less frequently as GG ≥3 patients. Addition
of tissue biomarkers, such as PTEN, to the analysis might fur-
ther help stratify patients into proper follow-up or adjuvant
therapies [33,34].Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.humpath.2018.01.027.Acknowledgment
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